Glaspy JA - Search Results

1

PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez AJ, Grogan TR, Mateus C, Tomasic G, Glaspy JA, Emerson RO, Robins H, Pierce RH, Elashoff DA, Robert C, Ribas A. Tumeh PC, et al. Among authors: glaspy ja. Nature. 2014 Nov 27;515(7528):568-71. doi: 10.1038/nature13954. Nature. 2014. PMID: 25428505 Free PMC article. Clinical Trial.

2

Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma.

Vollmer CM Jr, Eilber FC, Butterfield LH, Ribas A, Dissette VB, Koh A, Montejo LD, Lee MC, Andrews KJ, McBride WH, Glaspy JA, Economou JS. Vollmer CM Jr, et al. Among authors: glaspy ja. Cancer Res. 1999 Jul 1;59(13):3064-7. Cancer Res. 1999. PMID: 10397245

3

Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein.

Butterfield LH, Koh A, Meng W, Vollmer CM, Ribas A, Dissette V, Lee E, Glaspy JA, McBride WH, Economou JS. Butterfield LH, et al. Among authors: glaspy ja. Cancer Res. 1999 Jul 1;59(13):3134-42. Cancer Res. 1999. PMID: 10397256

4

Characterization of antitumor immunization to a defined melanoma antigen using genetically engineered murine dendritic cells.

Ribas A, Butterfield LH, McBride WH, Dissette VB, Koh A, Vollmer CM, Hu B, Chen AY, Glaspy JA, Economou JS. Ribas A, et al. Among authors: glaspy ja. Cancer Gene Ther. 1999 Nov-Dec;6(6):523-36. doi: 10.1038/sj.cgt.7700076. Cancer Gene Ther. 1999. PMID: 10608349

5

Generation of T-cell immunity to a murine melanoma using MART-1-engineered dendritic cells.

Ribas A, Butterfield LH, Hu B, Dissette VB, Chen AY, Koh A, Amarnani SN, Glaspy JA, McBride WH, Economou JS. Ribas A, et al. Among authors: glaspy ja. J Immunother. 2000 Jan;23(1):59-66. doi: 10.1097/00002371-200001000-00008. J Immunother. 2000. PMID: 10687138

6

Immune deviation and Fas-mediated deletion limit antitumor activity after multiple dendritic cell vaccinations in mice.

Ribas A, Butterfield LH, Hu B, Dissette VB, Meng WS, Koh A, Andrews KJ, Lee M, Amar SN, Glaspy JA, McBride WH, Economou JS. Ribas A, et al. Among authors: glaspy ja. Cancer Res. 2000 Apr 15;60(8):2218-24. Cancer Res. 2000. PMID: 10786687

7

alpha-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination.

Meng WS, Butterfield LH, Ribas A, Dissette VB, Heller JB, Miranda GA, Glaspy JA, McBride WH, Economou JS. Meng WS, et al. Among authors: glaspy ja. Cancer Res. 2001 Dec 15;61(24):8782-6. Cancer Res. 2001. PMID: 11751399

8

CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells.

Ribas A, Butterfield LH, Amarnani SN, Dissette VB, Kim D, Meng WS, Miranda GA, Wang HJ, McBride WH, Glaspy JA, Economou JS. Ribas A, et al. Among authors: glaspy ja. Cancer Res. 2001 Dec 15;61(24):8787-93. Cancer Res. 2001. PMID: 11751400

9

Cancer immunotherapy using gene-modified dendritic cells.

Ribas A, Butterfield LH, Glaspy JA, Economou JS. Ribas A, et al. Among authors: glaspy ja. Curr Gene Ther. 2002 Feb;2(1):57-78. doi: 10.2174/1566523023348129. Curr Gene Ther. 2002. PMID: 12108974 Review.

10

Immunosuppressive effects of interleukin-12 coexpression in melanoma antigen gene-modified dendritic cell vaccines.

Ribas A, Amarnani SN, Buga GM, Butterfield LH, Dissette VB, McBride WH, Glaspy JA, Ignarro LJ, Economou JS. Ribas A, et al. Among authors: glaspy ja. Cancer Gene Ther. 2002 Nov;9(11):875-83. doi: 10.1038/sj.cgt.7700512. Cancer Gene Ther. 2002. PMID: 12386826

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

270 results

Search Page